Show simple item record

dc.contributor.authorMadec, Y
dc.contributor.authorLaureillard, D
dc.contributor.authorPinoges, L
dc.contributor.authorFernandez, M
dc.contributor.authorPrak, N
dc.contributor.authorNgeth, C
dc.contributor.authorMoeung, S
dc.contributor.authorSong, S
dc.contributor.authorBalkan, S
dc.contributor.authorFerradini, L
dc.contributor.authorQuillet, C
dc.contributor.authorFontanet, A
dc.date.accessioned2009-03-06T16:18:37Z
dc.date.available2009-03-06T16:18:37Z
dc.date.issued2007-01-30
dc.identifier.citationResponse to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. 2007, 21 (3):351-9 AIDSen
dc.identifier.issn0269-9370
dc.identifier.pmid17255742
dc.identifier.doi10.1097/QAD.0b013e328012c54f
dc.identifier.urihttp://hdl.handle.net/10144/52733
dc.description.abstractBACKGROUND: HAART efficacy was evaluated in a real-life setting in Phnom Penh (Médecins Sans Frontières programme) among severely immuno-compromised patients. METHODS: Factors associated with mortality and immune reconstitution were identified using Cox proportional hazards and logistic regression models, respectively. RESULTS: From July 2001 to April 2005, 1735 patients initiated HAART, with median CD4 cell count of 20 (inter-quartile range, 6-78) cells/microl. Mortality at 2 years increased as the CD4 cell count at HAART initiation decreased, (4.4, 4.5, 7.5 and 24.7% in patients with CD4 cell count > 100, 51-100, 21-50 and < or = 20 cells/microl, respectively; P < 10). Cotrimoxazole and fluconazole prophylaxis were protective against mortality as long as CD4 cell counts remained < or = 200 and < or = 100 cells/microl, respectively. The proportion of patients with successful immune reconstitution (CD4 cell gain > 100 cells/microl at 6 months) was 46.3%; it was lower in patients with previous ART exposure [odds ratio (OR), 0.16; 95% confidence interval (CI), 0.05-0.45] and patients developing a new opportunistic infection/immune reconstitution infection syndromes (OR, 0.71; 95% CI, 0.52-0.98). Similar efficacy was found between the stavudine-lamivudine-nevirapine fixed dose combination and the combination stavudine-lamivudine-efavirenz in terms of mortality and successful immune reconstitution. No surrogate markers for CD4 cell change could be identified among total lymphocyte count, haemoglobin, weight and body mass index. CONCLUSION: Although CD4 cell count-stratified mortality rates were similar to those observed in industrialized countries for patients with CD4 cell count > 50 cells/microl, patients with CD4 cell count < or = 20 cells/microl posed a real challenge to clinicians. Widespread voluntary HIV testing and counselling should be encouraged to allow HAART initiation before the development of severe immuno-suppression.
dc.language.isoenen
dc.rightsPublished by Wolters Kluwer Lippincott Williams & Wilkins Archived on this site by kind permission Wolters Kluweren
dc.subject.meshAIDS-Related Opportunistic Infectionsen
dc.subject.meshAdulten
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntibiotic Prophylaxisen
dc.subject.meshAntiretroviral Therapy, Highly Activeen
dc.subject.meshCD4 Lymphocyte Counten
dc.subject.meshCambodiaen
dc.subject.meshDeveloping Countriesen
dc.subject.meshEpidemiologic Methodsen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHumansen
dc.subject.meshImmunocompromised Hosten
dc.subject.meshMaleen
dc.subject.meshProgram Evaluationen
dc.subject.meshTreatment Outcomeen
dc.titleResponse to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.en
dc.contributor.departmentUnité d'Epidémiologie des Maladies Emergentes, Institut Pasteur, 25-28 rue du Docteur Roux, 75015 Paris, France.en
dc.identifier.journalAIDS (London, England)en
refterms.dateFOA2019-03-04T12:18:03Z
html.description.abstractBACKGROUND: HAART efficacy was evaluated in a real-life setting in Phnom Penh (Médecins Sans Frontières programme) among severely immuno-compromised patients. METHODS: Factors associated with mortality and immune reconstitution were identified using Cox proportional hazards and logistic regression models, respectively. RESULTS: From July 2001 to April 2005, 1735 patients initiated HAART, with median CD4 cell count of 20 (inter-quartile range, 6-78) cells/microl. Mortality at 2 years increased as the CD4 cell count at HAART initiation decreased, (4.4, 4.5, 7.5 and 24.7% in patients with CD4 cell count > 100, 51-100, 21-50 and < or = 20 cells/microl, respectively; P < 10). Cotrimoxazole and fluconazole prophylaxis were protective against mortality as long as CD4 cell counts remained < or = 200 and < or = 100 cells/microl, respectively. The proportion of patients with successful immune reconstitution (CD4 cell gain > 100 cells/microl at 6 months) was 46.3%; it was lower in patients with previous ART exposure [odds ratio (OR), 0.16; 95% confidence interval (CI), 0.05-0.45] and patients developing a new opportunistic infection/immune reconstitution infection syndromes (OR, 0.71; 95% CI, 0.52-0.98). Similar efficacy was found between the stavudine-lamivudine-nevirapine fixed dose combination and the combination stavudine-lamivudine-efavirenz in terms of mortality and successful immune reconstitution. No surrogate markers for CD4 cell change could be identified among total lymphocyte count, haemoglobin, weight and body mass index. CONCLUSION: Although CD4 cell count-stratified mortality rates were similar to those observed in industrialized countries for patients with CD4 cell count > 50 cells/microl, patients with CD4 cell count < or = 20 cells/microl posed a real challenge to clinicians. Widespread voluntary HIV testing and counselling should be encouraged to allow HAART initiation before the development of severe immuno-suppression.


Files in this item

Thumbnail
Name:
Madec Cambodia.pdf
Size:
195.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record